Ra Pharmaceuticals Inc (NASDAQ:RARX) has been given a consensus rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $23.00.
RARX has been the topic of a number of research analyst reports. Raymond James upgraded Ra Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a research report on Wednesday, October 10th. BidaskClub downgraded Ra Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, October 5th. Credit Suisse Group boosted their price objective on Ra Pharmaceuticals from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Tuesday, August 7th. Zacks Investment Research downgraded Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, September 27th.
Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Ra Pharmaceuticals by 33.3% in the 3rd quarter. BlackRock Inc. now owns 2,049,933 shares of the company’s stock valued at $37,084,000 after buying an additional 512,602 shares during the period. First Manhattan Co. raised its holdings in shares of Ra Pharmaceuticals by 38.1% in the 3rd quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock valued at $19,426,000 after buying an additional 296,419 shares during the period. Millennium Management LLC raised its holdings in shares of Ra Pharmaceuticals by 50.9% in the 1st quarter. Millennium Management LLC now owns 671,262 shares of the company’s stock valued at $3,564,000 after buying an additional 226,565 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Ra Pharmaceuticals by 59.5% in the 1st quarter. JPMorgan Chase & Co. now owns 436,091 shares of the company’s stock valued at $2,315,000 after buying an additional 162,714 shares during the period. Finally, Candriam Luxembourg S.C.A. grew its stake in Ra Pharmaceuticals by 190.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 435,000 shares of the company’s stock worth $7,869,000 after purchasing an additional 285,000 shares in the last quarter. Hedge funds and other institutional investors own 73.36% of the company’s stock.
Ra Pharmaceuticals (NASDAQ:RARX) last posted its earnings results on Wednesday, November 7th. The company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.02). Equities analysts expect that Ra Pharmaceuticals will post -2.14 EPS for the current year.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
See Also: What is a Reverse Stock Split?
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.